Q32 Bio Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Q32 Bio Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.00-6.656.6533.972.701.675.32
Cost of Revenue0.4931.7335.8129.930.000.000.00
Gross Profit-0.49-38.38-29.1633.972.701.670.00
Operating Expenses
Research & Development48.1431.7398.3529.93100.3989.4047.95
Selling, General & Administrative17.479.8810.066.7632.5722.2117.30
Operating Expenses65.6141.6010.0636.69132.97111.6165.25
Operating Income-66.10-48.26-39.23-36.69-130.26-109.94-59.93
Other Income/Expense
Interest Income3.900.000.000.000.000.004.35
Interest Expense0.30-2.000.000.000.000.000.00
Other Income/Expense18.39-5.17-3.52-0.32-1.57-6.030.00
Income
Income Before Tax-47.71-53.43-42.75-37.02-128.69-103.92-55.58
Income Tax Expense0.020.320.060.550.000.000.00
Net Income-47.73-53.74-42.81-37.56-128.69-103.92-55.58
Net Income - Continuous Operations-47.73-53.74-42.81-37.560.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-45.30-47.76-38.86-36.65-120.93-97.60-58.64
EBIT-50.51-48.26-39.23-36.69-128.69-103.92-59.93
Depreciation & Amortization0.490.500.370.057.97-6.320.00
Earnings Per Share
Basic EPS-5.00-5.00-6.00-3.00-3.00--2.00
Diluted EPS-7.00-5.00-6.00-3.00-3.00-2.00-2.00
Basic Shares Outstanding12.2011.937.0311.9345.9142.1228.55
Diluted Shares Outstanding12.2011.937.0311.9345.9142.1228.55